Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin degludec/liraglutide injection - Tonghua Dongbao Pharmaceutical

Next Previous
X
Search
Drug Profile

Insulin degludec/liraglutide injection - Tonghua Dongbao Pharmaceutical

Alternative Names: Liraglutide injection/insulin degludec - Tonghua Dongbao Pharmaceutical

Latest Information Update: 23 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tonghua Dongbao Pharmaceutical
  • Class Antihyperglycaemics; Glucagon-like peptides; Insulins; Pancreatic hormones; Recombinant proteins
  • Mechanism of Action Glucagon receptor antagonists; Glucagon-like peptide-1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 19 Aug 2024 Tonghua Dongbao Pharmaceutical plans phase-III trial for Type 2 diabetes mellitus (In adults, In the elderly, Treatment-experienced, Adjunctive therapy) in August 2024 (SC, injection) (NCT06559722)
  • 15 May 2024 Phase-I clinical trials in Type 2 diabetes mellitus in China (SC)
  • 15 May 2024 National Medical Products Administration (NMPA) China approves IND application for Insulin degludec/liraglutide injection in Type 2 diabetes mellitus before May 2024 (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top